CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...